Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Division of Hematology/Oncology
University of Texas Southwestern Medical Center
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Senior Clinical Editor
Vice President, Scientific Services
Senior Director, Oncology Programs and Partnership Development
Senior Director, Educational Strategy
Hematology and Oncology
Senior Director, Educational Strategy
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose.
All of the relevant financial relationships of individuals for this activity have been mitigated.
This educational program is intended for medical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with CLL/SLL.
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC (CCO). Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour(s) in the area of pharmacology.
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-115-H01-P
Type of Activity: Knowledge
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learner information will be shared through the ACCME's Program and Activity Reporting System (PARS).
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 28, 2022, through October 27, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Downloadable slides on recent updates in R/R FL, with a focus on bispecific antibodies and CAR T-cell therapy, from Clinical Care Options (CCO)
Downloadable slides on recent updates in R/R FL, with a focus on second-line therapies and third-line epigenetic modifiers and PI3K inhibitors, from Clinical Care Options (CCO)
On-demand webcast from an ASH 2022 satellite symposium on BTK inhibitors for patients with CLL and MCL, from Clinical Care Options (CCO)
On-demand Clinical Care Options (CCO) webcast from a December 2022 symposium: experts discuss new care standards and evolving treatment strategies for aggressive B-cell lymphomas